Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo controlled study to investigate the safety and tolerability and clinical activity of 28 days of oral repeat dosing With GW856553 at 7.5mg BID in subjects with active rheumatoid arthritis on stable anti-rheumatic therapy

Next Previous
X
Search
Trial Profile

A randomized, double blind, placebo controlled study to investigate the safety and tolerability and clinical activity of 28 days of oral repeat dosing With GW856553 at 7.5mg BID in subjects with active rheumatoid arthritis on stable anti-rheumatic therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 11 May 2008 The expected completion date for this trial is now 1 Jan 2008.
    • 11 May 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Jun 2007 Status changed from initiated to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top